US fate of Auxilium drug in penis disease expected by early September
This article was originally published in Scrip
Executive Summary
Shares of Auxilium Pharmaceuticals got a slight 1.47% bump on 27 December after the company said the US FDA has accepted for review the firm's supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) as a treatment for Peyronie's disease, a rare progressive condition in which collagen plaque or scar tissue develops on the shaft of the penis, hardening and reducing flexibility, thus causing pain and forcing the penis to bend or arc during erection, often preventing intercourse.